{"count": 35, "results": [{"_id": "35932912", "pmid": 35932912, "title": "Choice of antihypertensive agent in isolated systolic hypertension and isolated diastolic hypertension: A secondary analysis of the ALLHAT trial.", "journal": "Am Heart J", "authors": ["Wang SY", "Hanna JM", "Gongal P", "Onuma OK", "Nanna MG"], "date": "2022-12-01T00:00:00Z", "doi": "10.1016/j.ahj.2022.07.006", "meta_date_publication": "2022 Dec", "meta_volume": "254", "meta_issue": "", "meta_pages": "30-34", "score": 50241.984, "text_hl": "We compared the use of @CHEMICAL_Chlorthalidone @CHEMICAL_MESH:D002752 @@@chlorthalidone@@@, @CHEMICAL_Amlodipine @CHEMICAL_MESH:D017311 @@@amlodipine@@@, or @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ on the primary outcome of combined @DISEASE_Coronary_Disease @DISEASE_MESH:D003327 @@@coronary heart disease@@@, @<m>DISEASE_Stroke</m> @DISEASE_MESH:D020521 @@@stroke@@@, or all-cause mortality in @SPECIES_9606 @@@patients@@@ with isolated @DISEASE_Isolated_Systolic_Hypertension @DISEASE_MESH:D000092244 @@@systolic hypertension@@@ or isolated @DISEASE_Hypertension_Diastolic_Resistance_to @DISEASE_MESH:C563897 @@@diastolic hypertension@@@.", "citations": {"NLM": "Wang SY, Hanna JM, Gongal P, Onuma OK, Nanna MG. Choice of antihypertensive agent in isolated systolic hypertension and isolated diastolic hypertension: A secondary analysis of the ALLHAT trial. Am Heart J. 2022 Dec;254():30-34. PMID: 35932912", "BibTeX": "@article{35932912, title={Choice of antihypertensive agent in isolated systolic hypertension and isolated diastolic hypertension: A secondary analysis of the ALLHAT trial.}, author={Wang SY and Hanna JM and Gongal P and Onuma OK and Nanna MG}, journal={Am Heart J}, volume={254}, pages={30-34}}"}}, {"_id": "40642858", "pmid": 40642858, "title": "Navigating Fabry Disease in a Military Aviator.", "journal": "Aerosp Med Hum Perform", "authors": ["Carlock T", "Kincaid-Sharp E", "Orsello C", "Ford AW", "El-Khoury BB"], "date": "2025-06-01T00:00:00Z", "doi": "10.3357/AMHP.6632.2025", "meta_date_publication": "2025 Jun", "meta_volume": "96", "meta_issue": "6", "meta_pages": "525-529", "score": 50231.855, "text_hl": "Initial evaluations revealed @DISEASE_Kidney_Diseases @DISEASE_MESH:D007674 @@@proteinuric kidney disease@@@ and an otherwise normal neurological workup indicating early @DISEASE_Fabry_Disease @DISEASE_MESH:D000795 @@@FD@@@, prompting initiation of @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@, @CHEMICAL_Clopidogrel @CHEMICAL_MESH:D000077144 @@@clopidogrel@@@ for @<m>DISEASE_Stroke</m> @DISEASE_MESH:D020521 @@@stroke@@@ prevention, and the newly Food and Drug Administration-approved chaperone therapy @CHEMICAL_migalastat @CHEMICAL_MESH:C090092 @@@migalastat@@@. ", "citations": {"NLM": "Carlock T, Kincaid-Sharp E, Orsello C, Ford AW, El-Khoury BB. Navigating Fabry Disease in a Military Aviator. Aerosp Med Hum Perform. 2025 Jun;96(6):525-529. PMID: 40642858", "BibTeX": "@article{40642858, title={Navigating Fabry Disease in a Military Aviator.}, author={Carlock T and Kincaid-Sharp E and Orsello C and Ford AW and El-Khoury BB}, journal={Aerosp Med Hum Perform}, volume={96}, number={6}, pages={525-529}}"}}, {"_id": "25455006", "pmid": 25455006, "title": "Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT.", "journal": "J Am Soc Hypertens", "authors": ["Yamal JM", "Oparil S", "Davis BR", "Alderman MH", "Calhoun DA", "Cushman WC", "Fendley HF", "Franklin SS", "Habib GB", "Pressel SL", "Probstfield JL", "Sastrasinh S", "ALLHAT Collaborative Research Group"], "date": "2014-11-01T00:00:00Z", "doi": "10.1016/j.jash.2014.08.003", "meta_date_publication": "2014 Nov", "meta_volume": "8", "meta_issue": "11", "meta_pages": "808-19", "score": 50066.445, "text_hl": "@<m>DISEASE_Stroke</m> @DISEASE_MESH:D020521 @@@Stroke@@@ outcomes among @SPECIES_9606 @@@participants@@@ randomized to @CHEMICAL_Chlorthalidone @CHEMICAL_MESH:D002752 @@@chlorthalidone@@@, @CHEMICAL_Amlodipine @CHEMICAL_MESH:D017311 @@@amlodipine@@@ or @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ in ALLHAT.", "citations": {"NLM": "Yamal JM, Oparil S, Davis BR, Alderman MH, Calhoun DA, Cushman WC, Fendley HF, Franklin SS, Habib GB, Pressel SL, Probstfield JL, Sastrasinh S, ALLHAT Collaborative Research Group. Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT. J Am Soc Hypertens. 2014 Nov;8(11):808-19. PMID: 25455006", "BibTeX": "@article{25455006, title={Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT.}, author={Yamal JM and Oparil S and Davis BR and Alderman MH and Calhoun DA and Cushman WC and Fendley HF and Franklin SS and Habib GB and Pressel SL and Probstfield JL and Sastrasinh S and ALLHAT Collaborative Research Group}, journal={J Am Soc Hypertens}, volume={8}, number={11}, pages={808-19}}"}}, {"_id": "2537566", "pmid": 2537566, "title": "Hemodynamic effects of lisinopril after long-term administration in congestive heart failure.", "journal": "Am J Cardiol", "authors": ["Stone CK", "Uretsky BF", "Linnemeier TJ", "Shah PK", "Amin DK", "Snapinn SM", "Rush JE", "Langendörfer A", "Liang CS"], "date": "1989-03-01T00:00:00Z", "doi": "10.1016/0002-9149(89)90900-4", "meta_date_publication": "1989 Mar 1", "meta_volume": "63", "meta_issue": "9", "meta_pages": "567-70", "score": 50062.9, "text_hl": "@<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@Lisinopril@@@ did not change @<m>DISEASE_Stroke</m> @DISEASE_MESH:D020521 @@@stroke@@@ work index at either initial or rechallenge study. ", "citations": {"NLM": "Stone CK, Uretsky BF, Linnemeier TJ, Shah PK, Amin DK, Snapinn SM, Rush JE, Langendörfer A, Liang CS. Hemodynamic effects of lisinopril after long-term administration in congestive heart failure. Am J Cardiol. 1989 Mar 1;63(9):567-70. PMID: 2537566", "BibTeX": "@article{2537566, title={Hemodynamic effects of lisinopril after long-term administration in congestive heart failure.}, author={Stone CK and Uretsky BF and Linnemeier TJ and Shah PK and Amin DK and Snapinn SM and Rush JE and Langendörfer A and Liang CS}, journal={Am J Cardiol}, volume={63}, number={9}, pages={567-70}}"}}, {"_id": "21676221", "pmid": 21676221, "pmcid": "PMC3141530", "title": "Paramedic Initiated Lisinopril For Acute Stroke Treatment (PIL-FAST): study protocol for a pilot randomised controlled trial", "journal": "Trials", "authors": ["Shaw L", "Price C", "McLure S", "Howel D", "McColl E", "Ford GA"], "date": "2011-06-15T00:00:00Z", "doi": "10.1186/1745-6215-12-152", "meta_date_publication": "2011 Jun 15", "meta_volume": "12", "meta_issue": "", "meta_pages": "152", "score": 50059.844, "text_hl": "Paramedic Initiated @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@Lisinopril@@@ For @<m>DISEASE_Stroke</m> @DISEASE_MESH:D020521 @@@Acute Stroke@@@ Treatment (PIL-@GENE_FASTK @GENE_10922 @@@FAST@@@): study protocol for a pilot randomised controlled trial", "citations": {"NLM": "Shaw L, Price C, McLure S, Howel D, McColl E, Ford GA. Paramedic Initiated Lisinopril For Acute Stroke Treatment (PIL-FAST): study protocol for a pilot randomised controlled trial Trials. 2011 Jun 15;12():152. PMID: 21676221", "BibTeX": "@article{21676221, title={Paramedic Initiated Lisinopril For Acute Stroke Treatment (PIL-FAST): study protocol for a pilot randomised controlled trial}, author={Shaw L and Price C and McLure S and Howel D and McColl E and Ford GA}, journal={Trials}, volume={12}, pages={152}}"}}, {"_id": "24078198", "pmid": 24078198, "pmcid": "PMC4251169", "title": "Paramedic Initiated Lisinopril For Acute Stroke Treatment (PIL-FAST): results from the pilot randomised controlled trial", "journal": "Emerg Med J", "authors": ["Shaw L", "Price C", "McLure S", "Howel D", "McColl E", "Younger P", "Ford GA"], "date": "2014-12-01T00:00:00Z", "doi": "10.1136/emermed-2013-202536", "meta_date_publication": "2014 Dec", "meta_volume": "31", "meta_issue": "12", "meta_pages": "994-9", "score": 50058.965, "text_hl": "...Paramedic Initiated @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@Lisinopril@@@ For @<m>DISEASE_Stroke</m> @DISEASE_MESH:D020521 @@@Acute Stroke@@@ Treatment flowchart.", "citations": {"NLM": "Shaw L, Price C, McLure S, Howel D, McColl E, Younger P, Ford GA. Paramedic Initiated Lisinopril For Acute Stroke Treatment (PIL-FAST): results from the pilot randomised controlled trial Emerg Med J. 2014 Dec;31(12):994-9. PMID: 24078198", "BibTeX": "@article{24078198, title={Paramedic Initiated Lisinopril For Acute Stroke Treatment (PIL-FAST): results from the pilot randomised controlled trial}, author={Shaw L and Price C and McLure S and Howel D and McColl E and Younger P and Ford GA}, journal={Emerg Med J}, volume={31}, number={12}, pages={994-9}}"}}, {"_id": "21183746", "pmid": 21183746, "title": "Pharmacogenetic effect of the stromelysin (MMP3) polymorphism on stroke risk in relation to antihypertensive treatment: the genetics of hypertension associated treatment study.", "journal": "Stroke", "authors": ["Sherva R", "Ford CE", "Eckfeldt JH", "Davis BR", "Boerwinkle E", "Arnett DK"], "date": "2011-02-01T00:00:00Z", "doi": "10.1161/STROKEAHA.110.593798", "meta_date_publication": "2011 Feb", "meta_volume": "42", "meta_issue": "2", "meta_pages": "330-5", "score": 50055.977, "text_hl": "RESULTS: Compared with participants treated with @CHEMICAL_Chlorthalidone @CHEMICAL_MESH:D002752 @@@chlorthalidone@@@ with the 6A/6A genotype, individuals with the 6A/6A genotype randomized to @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ had higher @<m>DISEASE_Stroke</m> @DISEASE_MESH:D020521 @@@stroke@@@ rates (hazard ratio=1.32; 95% CI, 1.08 to 1.61; P=0.007) and 5A/6A individuals taking @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ had lower @<m>DISEASE_Stroke</m> @DISEASE_MESH:D020521 @@@stroke@@@ rates (hazard ratio(interaction)=0.74; 95% CI, 0.53 to 1.04; P(interaction)=0.08), whereas 5A/5A individuals taking @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ had the lowest @<m>DISEASE_Stroke</m> @DISEASE_MESH:D020521 @@@stroke@@@ rate (hazard ratio(interaction)=0.51; 95% CI, 0.31 to 0.85; P(interaction)=0.009). ", "citations": {"NLM": "Sherva R, Ford CE, Eckfeldt JH, Davis BR, Boerwinkle E, Arnett DK. Pharmacogenetic effect of the stromelysin (MMP3) polymorphism on stroke risk in relation to antihypertensive treatment: the genetics of hypertension associated treatment study. Stroke. 2011 Feb;42(2):330-5. PMID: 21183746", "BibTeX": "@article{21183746, title={Pharmacogenetic effect of the stromelysin (MMP3) polymorphism on stroke risk in relation to antihypertensive treatment: the genetics of hypertension associated treatment study.}, author={Sherva R and Ford CE and Eckfeldt JH and Davis BR and Boerwinkle E and Arnett DK}, journal={Stroke}, volume={42}, number={2}, pages={330-5}}"}}, {"_id": "19352213", "pmid": 19352213, "title": "Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study.", "journal": "Pharmacogenet Genomics", "authors": ["Lynch AI", "Boerwinkle E", "Davis BR", "Ford CE", "Eckfeldt JH", "Leiendecker-Foster C", "Arnett DK"], "date": "2009-06-01T00:00:00Z", "doi": "10.1097/FPC.0b013e32832a8e81", "meta_date_publication": "2009 Jun", "meta_volume": "19", "meta_issue": "6", "meta_pages": "415-21", "score": 50054.04, "text_hl": "Genotype-by-treatment interactions (pharmacogenetic effects) were tested with the Cox regression. RESULTS: @<m>DISEASE_Stroke</m> @DISEASE_MESH:D020521 @@@Stroke@@@: common 'GG' homozygotes had higher risk on @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ versus @CHEMICAL_Amlodipine @CHEMICAL_MESH:D017311 @@@amlodipine@@@ [hazard ratio (HR)=1.38, P<0.001], whereas minor 'A' allele carriers had slightly lower risk (HR=0.96, P=0.76; P value for interaction=0.03). ", "citations": {"NLM": "Lynch AI, Boerwinkle E, Davis BR, Ford CE, Eckfeldt JH, Leiendecker-Foster C, Arnett DK. Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study. Pharmacogenet Genomics. 2009 Jun;19(6):415-21. PMID: 19352213", "BibTeX": "@article{19352213, title={Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study.}, author={Lynch AI and Boerwinkle E and Davis BR and Ford CE and Eckfeldt JH and Leiendecker-Foster C and Arnett DK}, journal={Pharmacogenet Genomics}, volume={19}, number={6}, pages={415-21}}"}}, {"_id": "9140680", "pmid": 9140680, "title": "Lisinopril in the treatment of congestive heart failure in elderly patients: comparison versus captopril.", "journal": "Cardiovasc Drugs Ther", "authors": ["Morisco C", "Condorelli M", "Crepaldi G", "Rizzon P", "Zardini P", "Villa G", "Argenziano L", "Trimarco B"], "date": "1997-03-01T00:00:00Z", "doi": "10.1023/a:1007704024393", "meta_date_publication": "1997 Mar", "meta_volume": "11", "meta_issue": "1", "meta_pages": "63-9", "score": 50053.28, "text_hl": "The maximal dose was @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ 20 mg once per day or @CHEMICAL_Captopril @CHEMICAL_MESH:D002216 @@@captopril@@@ 25 mg twice per day. ", "citations": {"NLM": "Morisco C, Condorelli M, Crepaldi G, Rizzon P, Zardini P, Villa G, Argenziano L, Trimarco B. Lisinopril in the treatment of congestive heart failure in elderly patients: comparison versus captopril. Cardiovasc Drugs Ther. 1997 Mar;11(1):63-9. PMID: 9140680", "BibTeX": "@article{9140680, title={Lisinopril in the treatment of congestive heart failure in elderly patients: comparison versus captopril.}, author={Morisco C and Condorelli M and Crepaldi G and Rizzon P and Zardini P and Villa G and Argenziano L and Trimarco B}, journal={Cardiovasc Drugs Ther}, volume={11}, number={1}, pages={63-9}}"}}, {"_id": "16864749", "pmid": 16864749, "title": "Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.", "journal": "Hypertension", "authors": ["Leenen FH", "Nwachuku CE", "Black HR", "Cushman WC", "Davis BR", "Simpson LM", "Alderman MH", "Atlas SA", "Basile JN", "Cuyjet AB", "Dart R", "Felicetta JV", "Grimm RH", "Haywood LJ", "Jafri SZ", "Proschan MA", "Thadani U", "Whelton PK", "Wright JT", "Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group"], "date": "2006-09-01T00:00:00Z", "doi": "10.1161/01.HYP.0000231662.77359.de", "meta_date_publication": "2006 Sep", "meta_volume": "48", "meta_issue": "3", "meta_pages": "374-84", "score": 50053.195, "text_hl": "No significant differences were found between treatment groups for the primary outcome, all-cause mortality, @DISEASE_Kidney_Failure_Chronic @DISEASE_MESH:D007676 @@@ESRD@@@, or @DISEASE_Neoplasms @DISEASE_MESH:D009369 @@@cancer@@@. @<m>DISEASE_Stroke</m> @DISEASE_MESH:D020521 @@@Stroke@@@ rates were higher on @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ in blacks (RR=1.51, 95% CI 1.22 to 1.86) but not in nonblacks (RR=1.07, 95% CI 0.89 to 1.28), and in @SPECIES_9606 @@@women@@@ (RR=1.45, 95% CI 1.17 to 1.79), but not in @SPECIES_9606 @@@men@@@ (RR=1.10, 95% CI 0.92 to 1.31). ", "citations": {"NLM": "Leenen FH, Nwachuku CE, Black HR, Cushman WC, Davis BR, Simpson LM, Alderman MH, Atlas SA, Basile JN, Cuyjet AB, Dart R, Felicetta JV, Grimm RH, Haywood LJ, Jafri SZ, Proschan MA, Thadani U, Whelton PK, Wright JT, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2006 Sep;48(3):374-84. PMID: 16864749", "BibTeX": "@article{16864749, title={Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.}, author={Leenen FH and Nwachuku CE and Black HR and Cushman WC and Davis BR and Simpson LM and Alderman MH and Atlas SA and Basile JN and Cuyjet AB and Dart R and Felicetta JV and Grimm RH and Haywood LJ and Jafri SZ and Proschan MA and Thadani U and Whelton PK and Wright JT and Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group}, journal={Hypertension}, volume={48}, number={3}, pages={374-84}}"}}]}